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An exaggerated blood pressure response to maximal exercise is an independent risk 
factor for cardiovascular events and mortality. It is unclear if treating blood pressure 
to guideline recommended levels could normalise the rise in blood pressure during 
exercise, which is mediated by the metaboreflex. We aimed to assess the blood 
pressure response to incremental exercise testing and metaboreflex activation in 
treated-controlled hypertension (n=16), treated-uncontrolled hypertension (n=16), 
and untreated-hypertension (n=11) and 16 control participants with normal blood 
pressure (n=16). All groups were matched for age and body mass index. Blood 
pressure was measured during an incremental VO2 peak test on a cycle ergometer 
and during metaboreflex isolation using post-exercise ischemia. Data were analysed 
using two-way analysis of variance with Tukey test for multiple comparisons. Aerobic 
fitness was similar among groups (P=0.97). The rise in absolute systolic blood 
pressure from baseline at peak exercise was similar in controlled-, uncontrolled- and 
untreated hypertension but greater compared to normotensive controls (delta 71±3 
,81±7, 79±8.5 vs. 47±5 mmHg, P=<0.0001). Metaboreflex sensitivity was also similar 
in controlled-, uncontrolled-, and untreated-hypertension but augmented compared 
to normotensive controls (delta systolic blood pressure; 21±2, 28±2, 25±3 vs. 12±2 
mmHg P=<0.0001). An amplified pressor response to exercise occurred in patients 
taking anti-hypertensive medication, despite having controlled blood pressure at rest 
and was potentially caused (in part) by enhanced metaboreflex sensitivity. Poor 
blood pressure control during exercise, partially mediated by the metaboreflex, may 
contribute to the heightened risk of an adverse cardiovascular event even in treated-
controlled patients.  
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Chronic aerobic endurance training lowers resting blood pressure (BP) in patients 
with hypertension 1. However, the acute rise in systolic BP (SBP) during both static 
and dynamic exercise, in patients with untreated or uncontrolled hypertension, is 
exaggerated compared to that observed in normotensive individuals 2-5. This is 
problematic as exaggerated increases in moderate and peak exercise SBP are 
associated with the risk of end organ damage (e.g. left ventricular hypertrophy) 6,7, 
cardiovascular disease (fatal and non-fatal) 8-11, stroke 10,12 and total mortality 11,13.  
 
Adjustments in the autonomic nervous system during exercise are mediated by feed-
forward signals from the brain (central command 14) as well as group III 
(mechanoreflex 15,) and group IV (metaboreflex 16) afferents that lie within the 
skeletal muscle (the exercise pressor reflex (EPR) 17). The mechanoreflex and 
metaboreflex are crucial for mediating the rise in sympathetic nerve activity (SNA) 
that occurs during exercise, which increases BP to augment skeletal muscle blood 
flow.  
 
In patients with untreated hypertension the level of SNA is elevated at both rest 18 
and during dynamic 19 and isometric 3 handgrip exercise. Since inhibition of the 
group III and IV muscle afferents, using intrathecal fentanyl, normalised the acute BP 
response to dynamic exercise in untreated hypertensives to levels attained in 
normotensive individuals, this demonstrated a major role of the EPR in controlling 
BP during exercise in this population 2.  Previous work in both animal models of 
hypertension 20,21 and humans 3-5,22 shows that the metaboreflex plays an important 
role in the exaggerated response of SNA and BP to exercise.  Little information is 
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available regarding the effect of anti-hypertensive medication on the SBP response 
to exercise, and the sensitivity of the metaboreflex. Studies have examined the BP 
response to exercise and the role of the metaboreflex only in untreated 
hypertensives 2 and mixed groups of hypertensives (untreated or withdrawn from 
anti-hypertensive medications 3-5). Although these studies have contributed to the 
knowledge base regarding the importance of exercise BP and the role of the 
metaboreflex, we do not know whether patients with treated-controlled hypertension 
have an exaggerated response to exercise and whether the metaboreflex remains 
hyperactive relative to age/sex matched normotensive controls. Exaggerated 
exercise BP was associated with depressed regression of left ventricular hypertrophy 
in patients with controlled hypertension, but no comparisons were made to 
normotensive controls7. This is important because despite treating BP to 
recommended levels, some studies show that patients with controlled BP at rest 
have an elevated risk of cardiovascular disease 23,24, all-cause mortality 23,25 and 
stroke 24 compared to normotensive controls. To explain this, we proposed that 
current anti-hypertensive medications do not act on the known mechanisms that 
sensitize the metaboreflex in hypertension (e.g. acid-sensing ion channels (ACIC), 
purinergic receptors (P2X) and transient receptor potential of the vanilloid type 1 
(TPRV1) 26,27) and thus cannot prevent the exaggerated spikes in BP during 
exercise. Thus, we hypothesised that the rise in BP during peak cardiopulmonary 
exercise and specific metaboreflex testing will be exaggerated in patients with 
controlled- and uncontrolled hypertension (similar to patients with untreated 





The analytic methods and summary data tables that support the findings of this study 
are available from the authors on request. 
 
Participants 
We recruited 59 participants; 16 normotensives, 16 treated-uncontrolled, 16-treated-
controlled and 11 untreated hypertensives, matched for age, body mass index (BMI) 
and cardiovascular fitness (as measured by a volume of oxygen inspired (VO2) peak 
test). This study was approved by Southwest-Exeter NHS REC (16/SW/0004) and 
local Research and Development (R&D) approval. All participants provided their 
written informed consent prior to participation. Participant demographics are shown 
in Table 1. 29 of the participants (49%) were female and 27 (93%) of these were 
postmenopausal. Participants attended the Clinical Research and Imaging Centre-
Bristol at the same time of day and the lab conditions were at a set temperature 
(22C). All participants were asked to abstain from intense exercise 24-hours before 
the study. All experimental protocols conformed to the Declaration of Helsinki. See 




This was a case-control study. Investigators were blinded during analysis of data. 
 
Screening procedure 





VO2 peak testing 
VO2 peak was assessed by an incremental exercise test on an upright cycle 
ergometer (Love Medical, Manchester, UK).  See online supplementary methods for 




The metaboreflex was assessed using post-exercise ischemia (PEI) following 1 
minute of isometric handgrip exercise at 30% maximal voluntary contraction (MVC) 
(please see http://hyper.ahajournals.org for online supplement). PEI is the standard 
protocol to assess metaboreflex sensitivity in humans 16,28. Following isometric 
handgrip exercise an occlusion cuff was inflated on the arm that performed the 
handgrip exercise to suprasystolic pressures (>240 mmHg) to isolate the 
metaboreflex; this is the PEI period. The occlusion cuff remained inflated at 
suprasystolic pressures for 1.5 minutes during PEI 3,4. The period following exercise 
where the occlusion cuff remains inflated represents PEI and isolation of the 
metaboreflex 3-5,16.  The BP and heart rate (HR) response during PEI was used as the 
assessment of the metaboreflex response to exercise.  
 
Physiological monitoring during exercise 
BP was measured every 1.5 minutes during VO2 peak testing using an automated 
sphygmomanometer (manufactured specifically for exercise BP monitoring; Love 
Medical, Manchester, UK) on the left arm of the participant. A 12-lead 
electrocardiogram (ECG) (Love Medical, Manchester, UK) was used to measure HR 
during the VO2 peak test.  
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During static handgrip exercise and PEI the change in arterial BP was measured on 
a beat-to-beat basis using finger plethysmography (Finometer, FMS, Netherlands) 
and the change in HR was recorded using a 3-lead ECG. During static handgrip 




See online supplement for data analysis (please see http://hyper.ahajournals.org). 
 
Statistics 
Participant characteristics were compared using a one-way analysis of variance (one-
way ANOVA), with a Tukey test for multiple comparisons. Group averages 
(normotension, treated-controlled, treated-uncontrolled and untreated hypertension) 
of SBP, diastolic BP (DBP), mean arterial pressure (MAP) and HR during the VO2 
peak test were compared using a two-way analysis of variance (two-way ANOVA), 
with a Tukey test for multiple comparisons.   
 
The handgrip and PEI period were broken down in to 30 second periods (0-30s 
handgrip, 30-60s handgrip, PEI 1 (60-90s), 2 (90-120s) and 3 (120-150s) and the 
group averages were compared using an ordinary two-way ANOVA., with a Tukey 
test for multiple comparisons. Data are reported as mean +/- standard error. The α-






All participants were matched for age (P=0.73), BMI (P=0.25) and cardiovascular 
fitness (VO2 peak) (P>0.97) (see Table 1 and Table S1; please see 
http://hyper.ahajournals.org). There was a difference in daytime ambulatory SBP 
between groups (F=26.57, P=<0.0001). A Tukey post hoc showed that people with 
treated-uncontrolled hypertension (145±3 mmHg) had higher daytime ambulatory 
SBP compared to treated-controlled hypertensives (125±2 mmHg; P=<0.0001) and 
normotensives (120±2 mmHg; P=<0.0001). Untreated hypertensive patients had 
similar daytime ambulatory SBP when compared to the treated-uncontrolled group 
(145±3 vs. 145±3 mmHg respectively; P=0.99) but higher than treated-controlled 
hypertensives (125±2 mmHg; P=<0.0001) and normotensives (120±2; P=<0.0001). 
Importantly, treated controlled hypertensives had a similar SBP to normotensive 
controls (125±2 vs.120±2 mmHg; P=0.37). Similar results were found in daytime 
ambulatory DBP (please see http://hyper.ahajournals.org for the online supplement 
for results regarding ambulatory DBP and HR). Anti-hypertensive medication is 
shown in Table 1. No participants had received device or surgical interventions to 
treat their hypertension.  
 
VO2 peak test 
There was an interaction between group and % of VO2 peak on the change in SBP (F 
(15,330) = 2.86, P=0.0003). The Tukey post-hoc test showed that the absolute 
increase in SBP from baseline during low intensity exercise (0-25, 26-50% VO2 peak) 
was similar between all groups (P>0.05; Figure 1a). However, during moderate-high 
intensity exercise (51-75% VO2 peak) the treated-uncontrolled and the treated-
controlled hypertensive group had comparable exaggerated increases in absolute 
SBP that were larger compared to normotensive controls (P=0.008 and P=0.046 
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respectively; Figure 1a). Similarly, at peak exercise treated-controlled, treated-
uncontrolled and untreated hypertensives had a comparable increase in SBP that 
were greater compared to normotensive controls (P=<0.0001, P=<0.0001 and 
P=<0.0001 respectively; Figure 1a). We also found similar results when assessing the 
absolute SBP and % change in SBP measured at each progressive exercise intensity 
(Figure S1A and S2A; please see http://hyper.ahajournals.org for the online 
supplement). The absolute SBP change per minute of VO2 peak test (ΔSBP/min) was 
significantly different between groups (F=5.762, P=0.0017). The increase in absolute 
SBP per minute of the VO2 peak test (ΔSBP/min) was similar in treated-controlled, 
treated-uncontrolled and untreated hypertension but higher than in normotensive 
controls (8±1,8±1, 8±1 vs. 5±0 mmHg respectively; P=0.0190, P=0.002 and P=0.023 
respectively).  
 
The DBP response to exercise was similar to the results found for SBP and can be 
found in the online supplement (please see http://hyper.ahajournals.org).  
 
There was an interaction between the groups and % of VO2 peak on the change in HR 
(F (15,275) = 2.032, P = 0.014). The rise in HR from baseline was similar between all 
groups up to 76-100% VO2 peak; at peak exercise untreated hypertensives had an 
exaggerated rise in absolute HR compared to treated-uncontrolled hypertensives 
(P=0.047; Figure 1d). At peak VO2, untreated hypertensives had a greater increase in 
absolute HR compared to normotensive controls and treated-uncontrolled 
hypertensives (P=0.011 and P=0.001; Figure 1d). Additionally, the rise in absolute HR 
was greater in the treated-controlled hypertensives compared to that measured in the 
treated-uncontrolled hypertension group and the normotensive controls at peak VO2 
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(P=0.003 and P=0.037: Figure 1d). Similar results were found at peak exercise (Figure 
1d). For respiratory data during the VO2 peak test, please see the online 
supplementary material (http://hyper.ahajournals.org). 
 
Handgrip exercise 
For results pertaining to data sampled during the isometric handgrip test, please see 
the online supplementary material (http://hyper.ahajournals.org).  
 
Metaboreflex 
Two treated-controlled hypertensive participants withdrew from the study following 
visit one, therefore, 14 treated-controlled hypertensives have completed metaboreflex 
testing. There was an interaction between the groups and time on the change in SBP 
during metaboreflex activation using PEI (F (15,265) = 4.222, P=<0.0001). The 
absolute increase in SBP, DBP, MAP and HR from baseline across all time points 
(isometric handgrip and PEI; 30s averages) are displayed in Figure 2a-d. The Tukey 
multiple comparisons post hoc test showed that the increase in SBP from baseline 
during all 30s epochs of PEI was similar between the treated-controlled, treated-
uncontrolled group and untreated hypertensive groups (P=>0.05).  
 
The treated-controlled, treated-uncontrolled and untreated hypertensive groups had a 
larger change in SBP compared to normotensive controls during PEI1 (P=<0.0001, 
P=0.087 and P=0.0004), PEI2 (P=<0.0001, P=0.042 and P=0.0002) and PEI3 
(P=<0.0001, P=0.0162 and P=0.0003 (Figure 2a). An example of an individual SBP 
response to both isometric handgrip exercise and metaboreflex isolation can be found 
on Figure S4 (please see the online supplement, http://hyper.ahajournals.org). 
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There was an interaction between the groups and time on the change in DBP during 
PEI (F (15,265) = 1.787, P= 0.036). The rise in DBP in treated-controlled and treated-
uncontrolled hypertensives remained similar during PEI (P=0.987) but exaggerated 
when compared to that measured in normotensive controls during PEI1 (P=0.0186 
and P=0.0482 respectively) and PEI2 (P=0.0252 and P=0.0278 respectively) (Figure 
2b). During PEI3, only treated-controlled hypertensives had an exaggerated change 
in DBP compared to normotensives (P=0.032). There were no group differences in 
HR response PEI (F (15,260) = 1.306, P=0.198 respectively; Figure 2d). 
 
Discussion 
Our novel finding is that the increase in SBP during maximal exercise testing (VO2 
peak testing) is exaggerated in patients with treated-controlled hypertension (similar 
to that seen in treated-uncontrolled and untreated patients) compared to age; BMI and 
cardiovascular fitness (VO2 peak) matched normotensive controls. Additionally, the 
change in SBP during metaboreflex isolation (PEI) was exaggerated in treated-
controlled hypertension, similar to treated-uncontrolled and untreated hypertensives. 
We posit that the metaboreflex plays a role in driving this abnormal BP response to 
dynamic and static exercise in humans with treated and untreated hypertension. Given 
the inability of current antihypertensive medication to control BP during exercise, we 
are prompted to discuss fundamental changes in the clinical assessment and 
treatment of BP.  
 
SBP responses to exercise and cardiovascular risk  
The current goal of anti-hypertensive treatment is to lower resting BP, to achieve 
guideline recommended targets and reduce the risk of future adverse cardiovascular 
 13 
 
events. BP responses to exercise are not usually considered despite the fact that 
exaggerated responses are predictive of end organ damage 6,7, cardiovascular 
disease 8,9, ischemic stroke 10,12, acute myocardial infarction10 and total mortality 13. 
Our data indicate, for the first time, that an exaggerated BP response to exercise 
persists despite patients achieving guideline recommended BP targets with 
medication. This may explain why treated-controlled hypertensive patients have an 
elevated risk of cardiovascular events and mortality versus people with normotension 
23-25. Potentially, exercise BP should be considered in routine BP assessment by 
clinicians. Said differently, measuring BP while resting in a chair will not fully reveal 
the cardiovascular risk of a patient.  
 
The metaboreflex 
Data from animals 20,21,29 and humans 3-5 show that the muscle metaboreflex is 
exaggerated in people with hypertension; we have confirmed these findings in 
humans. Previous research focusing on hypertension and the metaboreflex in humans 
has focused on untreated hypertensive patients 22 or a mixture of untreated 
hypertensive and treated hypertensives withdrawn from their medication 3-5. Our novel 
data indicate that in patients with treated-controlled hypertension the sensitivity of the 
metaboreflex is increased, contributing to the elevated BP response to exercise in this 
cohort. This is important because studies in hypertensive dogs showed that an 
exaggerated muscle metaboreflex caused coronary vasoconstriction during exercise, 
which limited the exercise induced increase in cardiac output 29. Therefore, coronary 
perfusion during exercise could be impacted in hypertensive humans if metaboreflex 




We did not find an exaggerated HR response to metaboreflex isolation, which is similar 
to previous findings using isometric handgrip exercise in human hypertension 3,4. 
Typically, SNA responses to PEI, measured using microneurography (muscle SNA; 
MSNA) are exaggerated in hypertensive patients 3,5. This has been confirmed in 
animal models of hypertension by measuring renal SNA during metaboreflex isolation 
20. Therefore, it is probable that increased MSNA responses to metaboreflex activation 
caused the increased BP in our patients. However, this was not directly measured.  
 
The other component of the EPR, the mechanoreflex has also been shown to 
contribute to the exaggerated BP response to exercise in untreated hypertension 30. 
We focused solely on the metaboreflex since previous data in untreated hypertension 
highlights its importance 3-5,22,31 and due to difficulties in isolating the mechanoreflex 




Exactly what drives the increased metaboreflex response to exercise in hypertension 
is unclear. It is probable that there is a supply and demand mismatch due to 
inadequate perfusion of the active vascular bed 19,32. In healthy individuals, during 
exercise, the increased SNA directed towards the skeletal muscle is normally offset 
by locally produced vasodilatory metabolites (functional sympatholysis) 19,32. In 
untreated hypertensives, functional sympatholysis is impaired, owing to altered nitric 
oxide signalling (in part due to endothelial damage and/or increased oxidative stress 
within the muscle 32,33). This is combined with exaggerated SNA responses to 
exercise, leading to reductions in muscle perfusion and increased metabolites that 
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activate the metaboreflex 19,32,34. Therefore, an impaired functional sympatholysis 
could also explain exaggerated metaboreflex sensitivity in treated-controlled 
hypertension. It could be postulated that standard first line anti-hypertensive 
medications (e.g. ACE inhibitors, angiotensin II receptor blockers (ARB), calcium 
channel blockers and/or thiazide like diuretic 35) do not directly affect functional 
sympatholysis or metaboreflex sensitivity during exercise. However, this has not 
directly been assessed and requires future attention. For example, Irbesartan, an 
ARB, failed to improve functional sympatholysis or control of MSNA during dynamic 
handgrip exercise in untreated hypertensives 19. Other mechanisms could include 
alterations in the sensitivity/density of receptors sensitive to metabolites released 
during exercise, however, data supporting this concept is scant in hypertensives. The 
only study to date is by Mizuno et al 20; the authors found that TRPV1 receptor 
expression is increased in the dorsal root ganglia of the spontaneously hypertensive 
rat, indicating potential upregulation of the receptor.  
 
Given our findings of the inadequacies of antihypertensive drugs in controlling BP 
during exercise, any novel pharmacological interventions should consider reducing 
exercise SBP as well as resting BP. Potential targets could include chemically 
sensitive afferents and associated receptors in skeletal muscle. Since there are many 
receptors involved in the metaboreflex and much redundancy exists in humans 36, 
blocking one receptor may not effectively reduce the exercise pressor response 5,20,36. 
However, reducing metaboreflex sensitivity would be expected to reduce reflex 
increases in sympathetic vasoconstrictor activity to skeletal muscle and hence 




Putting the overt cardiovascular risk of acute exercise aside demonstrated herein, long 
term aerobic training (3-4 times per week) has improved functional sympatholysis in 
the femoral artery and subsequently the BP response to exercise of untreated 
hypertensive patients 34. Improvement of long-term cardiovascular fitness could be an 
effective method for improving the autonomic response to exercise in treated and 
untreated hypertension. However, adherence to exercise regimes is typically poor, 
highlighting the need for improved strategies to promote exercise training and/or 
physical activity in the community 37.  
 
Study Limitations 
There are several limitations. First, all the participants kept a 24-hour diary, which 
noted the times they took their medications; however, we cannot guarantee that 
treated-controlled and treated-uncontrolled hypertensives were taking their anti-
hypertensive medication(s). Participants were asked to take their anti-hypertensive 
medication as normal on study days. Second, the treated-controlled patients began 
the study already treated for their hypertension and took a variety of different classes 
of medication, which may have had different effects on exercise BP 38. Future 
studies should assess exercise BPs and metaboreflex sensitivity in treatment-naive 
hypertensives before and following effective anti-hypertensive treatment, assessing 
the effect of different types of anti-hypertensive medications. Third, PEI induced by 
circulatory occlusion can be perceived as painful for some participants. Patients who 
perceive a stimulus as more painful have an augmented BP response to the stimulus 
39. This could confound the BP response to PEI. We did not assess pain perception 
between groups, however, hypertensive patients have a blunted sensitivity to acute 
pain 39. Forth, we measured the BP response to incremental dynamic exercise 
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because this is predictive of future cardiovascular morbidity but activated the 
metaboreflex using circulatory occlusion following static handgrip exercise. Future 
studies will need to activate the metaboreflex during exercise as the cardiovascular 
response to metaboreflex activation is different when activated during exercise 
compared to PEI 40. It is also possible that anti-hypertensive medications alter the 
perception of effort of participants and in turn increase or decrease central 
command, which may have influenced the BP response to exercise 41. Finally, this 
was a single centre, case-controlled study which may limit its generalisability to other 
population groups. Comparing the BP response to metaboreflex activation following 
static exercise in a small muscle bed may not reflect how the metaboreflex is 
activated during dynamic exercise of a large muscle mass 42.  
 
Perspectives 
In the general population, Laukkanen et al. 10 found that individuals with a SBP rise of 
more than 64 mmHg at peak exercise are at most risk of an acute cardiovascular event 
10. We found a comparable rise in SBP (Δ72 mmHg) in the treated-controlled 
hypertensive cohort in this study. Additionally, hypertensive patients who present an 
exaggerated BP response to exercise are more likely to have reduced improvement 
of left ventricular hypertrophy when compared to hypertensives with a normal BP 
response to exercise 7. However, Mizuno et al 7 did not include a control group with 
normal resting BP. Considering our findings, it is important that future research 
assesses the long-term prognosis of an exaggerated BP response to exercise in 
treated-controlled hypertensives. If these results are confirmed in larger multicentre 
studies, it would suggest the need for routine BP assessment during exercise in 
patients with hypertension (controlled, uncontrolled or untreated). Controlled BP at 
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rest but an exaggerated response to exercise may indicate an underlying 
cardiovascular pathology, which has not been treated by standard anti-hypertensive 
treatment. Measuring BP during exercise may help to identify those patients who are 
at increased risk of adverse cardiovascular outcomes. Our data support the need for 
developing new treatment strategies that attenuate the exercise pressor response, 
such targets might include ASIC, TPRV and/or P2X receptors 26,27. Additionally, the 
SBP Intervention Trial (SPRINT) found that lowering SBP below 120 mmHg with 
intensive treatment resulted in fewer fatal and nonfatal cardiovascular events and 
death from any cause 43. Lower BP targets in line with the SPRINT trial may reduce 
the SBP response to exercise and blunt the sensitivity of the metaboreflex. This may 
contribute to why lower BP targets confer added cardiovascular protection 43. 
 
Conclusion 
This is the first study to show that the SBP responses to dynamic exercise (both 
submaximal and maximal) is augmented in patients with treated-controlled 
hypertension and is similar to that in patients with treated but uncontrolled and 
untreated hypertension. The exaggerated rise in SBP during moderate intensity 
exercise (i.e. at around 50% of VO2 peak) may explain why this cohort are at greater 
risk of future cardiovascular events. The metaboreflex plays a key role in the 
exaggerated rise in SBP during exercise in treated and untreated hypertension and 
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Novelty and Significance 
What Is New? 
• The BP response to peak exercise is similar in treated and untreated 
hypertensives and augmented compared to normotensive individuals. 
• The metaboreflex plays a part in regulating the exaggerated SBP response to 
peak exercise in treated and untreated hypertension. 
What Is Relevant? 
• Despite control of baseline BP, anti-hypertensive medication does not protect 
against exaggerated BP increases during peak exercise testing or 
metaboreflex testing. 
• An exaggerated rise in blood pressure during exercise could place treated 
and untreated hypertensives at increased risk of adverse cardiovascular 
events compared to normotensives. 
Summary 
This is the first study to show that treated-controlled hypertensives, despite adequate 
control of baseline BP, have a similar BP response compared to treated-uncontrolled 





Figure 1. The absolute change from baseline in A) Systolic blood pressure (SBP), B) 
diastolic blood pressure (DBP), C) Mean arterial pressure (MAP) and D) Heart rate 
(HR) during VO2 peak testing. Changes in hemodynamics are calculated at different 
percentages of VO2 peak and at peak exercise testing (VO2 peak) to enable 
comparisons between groups. * P=<0.05 for all groups vs. normotension. † P=<0.05 
uncontrolled hypertension vs. normotension. ‡ P=<0.05 controlled hypertension vs. 
normotension. § P=<0.05 controlled and uncontrolled hypertension vs. untreated 
hypertension. ││ P=<0.05 untreated hypertension vs. normotension. # P=<0.05 
controlled hypertension vs. uncontrolled hypertension. ** P=<0.05 uncontrolled 
hypertension vs. untreated hypertension.  
 
Figure 2. The absolute change from baseline in A) systolic blood pressure (SBP), B) 
diastolic blood pressure (DBP), C) mean arterial pressure (MAP) and D) heart rate 
(HR) during isometric handgrip exercise at 30% maximal voluntary contraction (0-30  
and 30-60s handgrip (HG), post-exercise ischemia (PEI) (30 second ± periods PEI1, 
2 and 3). * P=<0.05 for all groups vs. normotension. † P=<0.05 uncontrolled 







Table 1. Participant Characteristics 








N 16 11 16 16 
M/F 8/8 6/5 9/7 7/9 
Age (Years) 65±1 65±2 66±2 67±1 
Height (cm) 172±3 173±4 170±2 167±2 
Weight (kg) 70±4 72±4 74±3 72±4 
BMI (kg/m2) 23.4±0.8 24.1±1 25.5±0.9 25.3±0.8 
VO2 peak 
(ml/min/kg) 
22.6±1.4 23.5±2.1 22.8±1.9 22.3±1.2 
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N; number, M; male, F; female, BMI; body mass index, VO2 peak; peak volume of 
oxygen inspired, ABPM; ambulatory blood pressure monitoring, SBP; SBP, DBP; 
DBP, MAP, Heart rate; HR, ACEi; angiotensin converting enzyme inhibitor, ARB; 
angiotensin receptor blocker, CCB; calcium channel blocker, IQR; inter-quartile 
range. * P=<0.05 vs. normotension; †P=<0.05 vs. controlled hypertension (all one-
way ANOVA with Tukey post-hoc test). 
 
 
